ASX Announcement: 19 November 2026 (Melbourne, Australia)
Optiscan Imaging Ltd (ASX: OIL)

Extension of Time to Hold Annual General Meeting

Optiscan Imaging Limited (ASX: OIL) ('**Optiscan**' or the '**Company**') advises that the Australian Securities and Investments Commission (**ASIC**) has extended the period within which the Company must hold its Annual General Meeting (**AGM**) to 29 January 2027.

Optiscan sought an extension from ASIC under section 250P of the Corporations Act 2001 (*Cth*) (**Corporations Act**) to allow additional time to finalise its notice of meeting, including the resolutions and explanatory memorandum with the information required by the ASX Listing Rules and the Corporations Act, with sufficient time to provide the requisite notice period to Shareholders. Given the holiday period between 20 December 2026 and 26 January 2027, a meeting held on 29 January will allow voting and attendance by Shareholders outside the holiday period.

In accordance with ASX Listing Rule 3.13.1 and the Company's Constitution, for an AGM held on 29 January 2027, the closing date for receipt of a nomination and consent from persons wishing to be considered as a director is 5.00pm (AEDT) on Monday, 14 December 2026.

Optiscan's audited annual financial report was lodged with ASX and ASIC on 25 August 2026 and is available on the ASX platform and the Company's website. Should Shareholders have any questions in relation to the annual financial report or the extension of time to hold the AGM, please contact the Company Secretary at cosec@optiscan.com.

– ends –

This announcement has been authorised for release by the Board of Optiscan.

For further information, please contact:

Shareholder & General Enquiries
Optiscan Imaging Limited
Dr Camile Farah
T: +61 3 9538 3333
E: ceo@optiscan.com

Media & Investor Enquiries
The Capital Network
Julia Maguire
T: +61 2 7257 7338
E: julia@thecapitalnetwork.com.au

About Optiscan

Optiscan Imaging Limited (ASX: OIL) is a commercial stage medical technology company creating a suite of digital pathology and precision surgery hardware and software solutions that enable live optical biopsy for life sciences, diagnostic and surgical applications. Optiscan pioneered the development and manufacturing of miniaturised digital endomicroscopes with spatial resolution more than 1000x that of medical CT and MRI.

Using a revolutionary "tissue contact" method, Optiscan's patented technology produces super high-resolution digital pathology images for cancer diagnosis and surgical treatment, to unlock real-time insights during surgery, diagnostics, and pre-clinical research. By enabling live, non-destructive, 3D, in-vivo digital imaging at the single-cell level, Optiscan's technology supports earlier disease detection, precision treatment, and improved patient outcomes across a wide selection of clinical applications and settings.

The global addressable market for Optiscan's medical imaging technology extends beyond traditional surgery and pathology, to also encompass the fast-growing digital health market including robotic surgery. With an expanding product suite and increased demand for digital health solutions, Optiscan is uniquely positioned to bridge the gap between surgery and pathology and deliver better outcomes for healthcare professionals and their patients.

To learn more about Optiscan, visit www.optiscan.com or follow us on LinkedIn, X or Instagram.

Disclaimer

All statements other than statements of historical fact included on this announcement including, without limitation, statements regarding future plans and objectives of Optiscan or any of the other parties referred to herein, are forward-looking statements. Forward-looking statements can be identified by words such as 'anticipate", "believe", "could", "estimate", "expect", "future", "intend", "may", "opportunity", "plan", "potential", "project", "seek", "will" and other similar words that involve risks and uncertainties. These statements are based on an assessment of present economic and operating conditions, and on assumptions regarding future events and actions that are expected to take place. Such forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties, assumptions and other important factors, many of which are beyond the control of the Company, its directors and management of Optiscan that could cause actual results to differ from the results expressed or anticipated in these statements.